CD4 and COVID-19: SARS-CoV-2–reactive CD4+ T cells were detected in 34.2% (13/38) of non–COVID-19 controls, whereas 83.2% (79/95) of COVID-19 patients exhibited a SARS-CoV-2–specific response (Figure 2B).